The oncology-focused biotech granted inducement options vesting over four years to attract new employees.
Geron Corporation granted stock options for 690,000 shares to eight newly hired employees on June 17, 2026. The options carry an exercise price of $1.23 per share, matching the closing price on the grant date.
The options vest over four years, with 12.5% vesting after six months and the remainder over the next 42 months. The grants aim to incentivize new hires as part of the company’s growth strategy in oncology therapeutics.
Geron, trading on NASDAQ under the ticker GERN, recently participated in the Goldman Sachs Global Healthcare Conference earlier in June.